옵션 체인은 다양한 행사가격과 만기일에 대한 Poseida Therapeutics의 주식 옵션 주요 데이터를 보여줍니다. 트레이더들은 이 정보를 사용하여 잠재적 거래를 분석하고 Poseida Therapeutics에 대한 시장 심리를 평가합니다..

Poseida Therapeutics (NASDAQ:PSTX) 주식, 옵션 체인

Poseida Therapeutics

Poseida Therapeutics Inc is a clinical-stage biopharmaceutical company focused on leveraging non-viral gene engineering technologies to create life-saving therapeutics for patients with a high unmet medical need. It has built a pipeline of autologous and allogeneic chimeric antigen receptor T cell, or CAR-T, product candidates, initially focused on the treatment of hematological malignancies and solid tumours.

Earnings

News

Pre-Market Outlook

Markets

Trading Ideas

DELL

PSTX

화요일(26일) 아침 미국 주식 선물이 소폭 상승하고 있는 가운데, 오늘 투자자들의 주목을 받을 수 있는 주식은 다음과 같다. 베스트바이, 포세이다, HP, 줌 및 델 테크놀로지스

화요일 주목해야 할 주식: 베스트바이, 포세이다, HP, 줌 및 델 테크놀로지스

Poseida Therapeutics, Inc. - Common Stock

Poseida Therapeutics Inc

HC Wainwright &amp; Co. analyst Arthur He downgrades Poseida Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSTX#NASDAQ">PSTX</a>) from Buy to Neutral and lowers the price target from $20 to $9.

Downgrades

Price Target

Analyst Ratings

HC Wainwright & Co. Downgrades Poseida Therapeutics to Neutral, Lowers Price Target to $9

On Tuesday, Roche Holdings AG (OTC:<a class="ticker" href="https://www.benzinga.com/stock/RHHBY#OTC">RHHBY</a>) agreed to acquire Poseida Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSTX#NASDAQ">PSTX</a>) for an equity value of approximately&nbsp;$1.5 billion&nbsp;on a <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/n42180905/poseida-therapeutics-inc-announces-agreement-to-be-acquired-by-roche-holdings-inc" rel="noreferrer noopener">fully diluted basis</a>.
The deal consideration includes $9.00&nbsp;per share in cash plus a non-tradeable CVR to receive certain contingent payments of up to an aggregate of&nbsp;$4.00&nbsp;per share in cash upon achievement of specific milestones.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/10/41505575/roches-q3-sales-surge-led-by-ocrevus-vabysmo-urges-regulators-to-block-novo-holdings-16-5b-catale" rel="noreferrer noopener">Roche&#8217;s Q3 Sales Surge Led By Ocrevus, Vabysmo, Urges Regulators To Block Novo Holdings&#8217; $16.5B Catalent Acquisition</a>
The proposed acquisition will establish a new core capability for&nbsp;Roche in allogeneic cell therapy, with lead opportunities focused on CAR-T programs covered by the existing strategic collaboration between Poseida and Roche in hematologic malignancies.
It will include CAR-T programs for solid tumors and autoimmune diseases, Poseida&#8217;s genetic engineering platform, and related preclinical medicines.
The acquisition <a target="_blank" href="https://www.roche.com/media/releases/med-cor-2024-11-26b" rel="noreferrer noopener">supports</a> Roche&#8217;s Pharma Strategy and allows for a range of potentially first and best-in-class therapies across oncology, immunology, and neurology, uniquely positioning Roche in the new field of donor-derived off-the-shelf cell therapies.
In its third-quarter earnings release, Poseida said it has three programs under Roche collaboration announced in August 2022, including P-BCMA-ALLO1, an allogeneic CAR-T therapy in Phase 1/1b&nbsp;development for multiple myeloma, and P-CD19CD20-ALLO1, an allogeneic dual CAR-T candidate in Phase 1 development for <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/n41823822/poseida-therapeutics-provides-updates-and-financial-results-for-the-third-quarter-of-2024" rel="noreferrer noopener">B-cell malignancies</a>.&nbsp;
In October, Poseida Therapeutics nominated a new development candidate under its collaboration with Roche. The nomination triggered a&nbsp;$15 million&nbsp;milestone payment from Roche to Poseida.
The new candidate is an allogeneic, dual CAR-T therapy targeting known antigens expressed in <a target="_blank" href="https://www.benzinga.com/pressreleases/24/10/n41378041/poseida-therapeutics-announces-nomination-of-new-car-t-development-candidate-under-collaboration-w" rel="noreferrer noopener">hematologic malignancies</a>.
The transaction is expected to close in the first quarter of 2025.
Concurrently, Roche <a target="_blank" href="https://www.roche.com/media/releases/med-cor-2024-11-26" rel="noreferrer noopener">revealed</a> an update on the Phase 3 SKYSCRAPER-01 study of tiragolumab combined with Tecentriq (atezolizumab) compared to Tecentriq alone for PD-L1-high, locally advanced or metastatic non-small cell lung cancer (NSCLC).&nbsp;
The 534-patient study did not reach the primary endpoint of overall survival at the final analysis.
The overall safety profile observed remained consistent with longer follow-up, and no new safety signals were identified. The detailed data will be presented at a medical meeting in 2025.
Roche regularly evaluates its research programs to see if changes are needed to support ongoing studies. The same approach will be applied to this program, with more data from Phase 3 trials in various settings or tumor types expected next year.
Price Action: PSTX stock is up 227.3% at $9.36 during the premarket session at last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/11/42184005/rivian-to-expand-us-ev-production-with-66-billion-doe-loan" target="_blank" rel="noreferrer noopener">Rivian Rides High: $6.6 Billion DOE Loan Commitment Fuels EV Expansion</a></li>
</ul>
Photo via Shutterstock.

Biotech

Equities

Health Care

Movers

General

RHHBY

Roche's Proposed Acquisition Of Poseida Therapeutics Poised To Establish New Core Capability In Cell Therapy For Cancer And Autoimmune Diseases: Details

WIIM

Poseida Therapeutics shares are trading higher after the company announced it will be acquired by Roche in a $1.5 billion deal, with stockholders receiving up to $13 per share in cash.

Shares of Poseida Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSTX#NASDAQ">PSTX</a>) rose sharply in today's pre-market trading after the company <a href="https://www.benzinga.com/quote/PSTX/news">agreed to be acquired by Roche in a $1.5 billion deal.</a>
Poseida Therapeutics shares jumped 218.8% to $9.12 in the pre-market trading session.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>ZenaTech, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZENA#NASDAQ">ZENA</a>) gained 61.5% to $10.37 in pre-market trading after climbing around 259% on Monday.</li>
<li>T Stamp Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IDAI#NASDAQ">IDAI</a>) rose 52.8% to $0.2750 in pre-market trading.</li>
<li>Spectral AI, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDAI#NASDAQ">MDAI</a>) gained 33.6% to $1.7500 in pre-market trading after gaining around 10% on Monday.</li>
<li>Channel Therapeutics Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHRO#NASDAQ">CHRO</a>) gained 22.7% to $0.7400 in pre-market trading after declining around 9% on Monday.</li>
<li>Hesai Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSAI#NASDAQ">HSAI</a>) climbed 20% to $5.70 in pre-market trading after the company posted upbeat quarterly sales.</li>
<li>Semtech Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMTC#NASDAQ">SMTC</a>) gained 18% to $63.06 in pre-market trading after the company reported better-than-expected third-quarter financial results and issued fourth-quarter guidance with its midpoint above estimates.</li>
<li>SEALSQ Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LAES#NASDAQ">LAES</a>) gained 16.9% to $0.5499 in pre-market trading after gaining 4% on Monday.</li>
<li>Onconetix, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONCO#NASDAQ">ONCO</a>) gained 14.9% to $0.9179 in pre-market trading after dipping around 27% on Monday.  </li>
<li>Woodward, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WWD#NASDAQ">WWD</a>) gained 10.7% to $198.55 in pre-market trading after the company reported better-than-expected quarterly EPS and sales.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>Alector, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALEC#NASDAQ">ALEC</a>) shares tumbled 31.3% to $2.72 in pre-market trading after the company announced that the INVOKE-2 Phase 2 clinical trial evaluating the safety and efficacy of AL002 in individuals with early Alzheimer&#8217;s disease failed to meet its primary endpoint.</li>
<li>Leslie&#8217;s, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LESL#NASDAQ">LESL</a>) shares fell 18.5% to $2.86 in pre-market trading after the company reported worse-than-expected fourth-quarter adjusted EPS and sales.</li>
<li>Quantum Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QMCO#NASDAQ">QMCO</a>) shares fell 16% to $18.29 in pre-market trading. Quantum shares jumped 138% on Monday after Amazon announced it has launched its Quantum Embark Program.</li>
<li>YXT.COM Group Holding Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YXT#NASDAQ">YXT</a>) fell 14.6% to $2.52 in pre-market trading.</li>
<li>Procaps Group SA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PROC#NASDAQ">PROC</a>) declined 12.6% to $1.11 in pre-market trading after surging 38% on Monday.</li>
<li>Kingsoft Cloud Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KC#NASDAQ">KC</a>) shares dipped 10.5% to $6.22 in pre-market trading.</li>
<li>Quantum Computing Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QUBT#NASDAQ">QUBT</a>) fell 8.1% to $7.07 in pre-market trading. Quantum Computing shares jumped 26% on Monday after AWS announced Quantum Embark program.</li>
<li>Electrovaya Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELVA#NASDAQ">ELVA</a>) fell 8.1% to $2.50 in pre-market trading after gaining 13% on Monday.</li>
<li>Zoom Video Communications, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZM#NASDAQ">ZM</a>) fell 7.8% to $82.02 in today's pre-market trading. Zoom Video posted better-than-expected results for its third quarter and raised its guidance for the full year.</li>
<li>Wearable Devices Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WLDS#NASDAQ">WLDS</a>) dipped 5.8% to $2.60 in pre-market trading after jumping over 46% on Monday.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/24/11/42181602/dow-sp-500-reach-fresh-highs-investor-sentiment-improves-fear-greed-index-remains-in-greed-zone">Dow, S&amp;P 500 Reach Fresh Highs: Investor Sentiment Improves, Fear Index Remains In &#8216;Greed&#8217; Zone</a></li>
</ul>

ALEC

CHRO

ELVA

HSAI

IDAI

LAES

LESL

MDAI

ONCO

PROC

QMCO

QUBT

SMTC

WLDS

ZENA

Why Poseida Therapeutics Shares Are Trading Higher By 219%; Here Are 20 Stocks Moving Premarket

With U.S. stock futures trading slightly higher this morning on Tuesday, some of the stocks that may grab investor focus today are as follows:
<ul>
<li>Wall Street expects Best Buy Co., Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBY#NYSE">BBY</a>) to report quarterly earnings at $1.29 per share on revenue of $9.63 billion before the opening bell, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>. Best Buy shares rose 0.4% to $93.37 in after-hours trading.</li>
<li>Poseida Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSTX#NASDAQ">PSTX</a>) agreed to be acquired by Roche in a $1.5 billion deal. Poseida Therapeutics shares jumped 11.2% to $3.18 in the after-hours trading session.</li>
<li>Analysts expect HP Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HPQ#NYSE">HPQ</a>) to post quarterly earnings at 93 cents per share on revenue of $13.99 billion. The company will release earnings after the markets close. HP shares fell 0.3% to $39.19 in after-hours trading.</li>
</ul>
Check out our <a href="https://www.benzinga.com/premarket/">premarket coverage here</a>
<ul>
<li>Zoom Video Communications, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZM#NASDAQ">ZM</a>) posted better-than-expected results for its third quarter and raised its guidance for the full year. Zoom reported third-quarter revenue of $1.18 billion, beating the consensus estimate of $1.16 billion. The communications company reported third-quarter adjusted earnings of $1.38 per share, beating analyst estimates of $1.31 per share. Zoom shares fell 5.6% to $84.09 in the after-hours trading session.</li>
<li>Analysts expect Dell Technologies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DELL#NYSE">DELL</a>) to report quarterly earnings at $2.05 per share on revenue of $24.65 billion after the closing bell. Dell shares fell 0.8% to $143.00 in after-hours trading.</li>
</ul>
Check This Out: 
<ul>
<li><a href="https://www.benzinga.com/markets/24/11/42174548/jim-cramer-says-this-stock-is-a-bitcoin-play-and-he-prefers-to-own-bitcoin">Jim Cramer Says This Stock Is A Bitcoin Play And He Prefers To Own Bitcoin</a></li>
</ul>
Photo courtesy: Flickr

Best Buy, HP And 3 Stocks To Watch Heading Into Tuesday

Poseida stockholders to receive up to $13.00 per share in cash, comprised of $9.00 per share in cash at closing and a non-tradeable contingent value right (CVR) to receive up to an aggregate of $4.00 per share in cash; transaction represents total equity value of up to $1.5 billion
Poseida to join the Roche Group and advance its innovative pipeline of non-viral, TSCM-rich CAR-T therapies and genetic medicines as part of Roche's Pharmaceuticals

Poseida Therapeutics To Be Acquired bB Roche In $1.5B Deal, Stockholders To Receive Up To $13/ Share In Cash

In the latest quarter, 4 analysts provided ratings for Poseida Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSTX#NASDAQ">PSTX</a>), showcasing a mix of bullish and bearish perspectives.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Poseida Therapeutics, presenting an average target of $20.0, a high estimate of $20.00, and a low estimate of $20.00. This current average has not changed from the previous average price target. 
<img src="https://www.benzinga.com/files/images/story/2024/1731679215_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
The standing of Poseida Therapeutics among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Arthur He</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$20.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Arthur He</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$20.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Arthur He</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$20.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Arthur He</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$20.00</td>
<td>$20.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Poseida Therapeutics. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Poseida Therapeutics compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Poseida Therapeutics's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Poseida Therapeutics's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/PSTX/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Poseida Therapeutics analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Discovering Poseida Therapeutics: A Closer Look</h2>
Poseida Therapeutics Inc is a clinical-stage biopharmaceutical company focused on leveraging non-viral gene engineering technologies to create life-saving therapeutics for patients with a high unmet medical need. It has built a pipeline of autologous and allogeneic chimeric antigen receptor T cell, or CAR-T, product candidates, initially focused on the treatment of hematological malignancies and solid tumours.
<h3>Poseida Therapeutics: A Financial Overview</h3>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Revenue Growth: Over the 3 months period, Poseida Therapeutics showcased positive performance, achieving a revenue growth rate of 667.19% as of 30 September, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.
Net Margin: Poseida Therapeutics's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 28.2%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Poseida Therapeutics's ROE excels beyond industry benchmarks, reaching 27.34%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Poseida Therapeutics's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 6.83%, the company showcases efficient use of assets and strong financial health.
Debt Management: Poseida Therapeutics's debt-to-equity ratio is notably higher than the industry average. With a ratio of 0.95, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Where Poseida Therapeutics Stands With Analysts

HC Wainwright &amp; Co. analyst Arthur He reiterates Poseida Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSTX#NASDAQ">PSTX</a>) with a Buy and maintains $20 price target.

Reiteration

HC Wainwright & Co. Reiterates Buy on Poseida Therapeutics, Maintains $20 Price Target

Poseida Therapeutics shares are trading higher after the company reported better-than-expected Q3 financial results.

Poseida Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSTX#NASDAQ">PSTX</a>) reported quarterly earnings of $0.21 per share which beat the analyst consensus estimate of $(0.41) by 151.22 percent. This is a 160 percent increase over losses of $(0.35) per share from the same period last year. The company reported quarterly sales of $71.75 million which beat the analyst consensus estimate of $16.27 million by 340.98 percent. This is a 667.19 percent increase over sales of $9.35 million the same period last year.

Earnings Beats

Poseida Therapeutics Q3 EPS $0.21 Beats $(0.41) Estimate, Sales $71.75M Beat $16.27M Estimate

New preclinical data on allogeneic CAR+TCR-T cells rich in stem cell memory T cells (TSCM) and enhanced potency to better target solid tumors will be presented at SITC
Additional profiling of patient responses in P-BCMA-ALLO1 Phase 1 Arm C and preclinical P-CD19CD20-ALLO1 to be presented at ASH
SAN DIEGO, Nov. 5, 2024 /PRNewswire/ --&nbsp;Poseida Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSTX#NASDAQ">PSTX</a>), a clinical-stage allogeneic cell therapy and genetic medicines company advancing differentiated non-viral treatments for patients with cancer, autoimmune and rare diseases, today announced new preclinical data on allogeneic CAR+TCR-T cells rich in stem cell memory T cells (TSCM), along with platform enhancements aimed at enhancing potency and improving targeting of solid tumors, will be presented at the Society for Immunotherapy of Cancer (SITC) 39th&nbsp;Annual Meeting in Houston, November 6-10.

Poseida Therapeutics To Present Clinical And Preclinical Data On Investigational Allogeneic CAR-T Cell Therapies At SITC 2024 And ASH 2024

Data to be highlighted in a Distinguished Industry Oral Abstract presentation at the American College of Allergy, Asthma &amp; Immunology (ACAAI) 2024 Scientific Meeting
SAN DIEGO, Oct. 24, 2024 /PRNewswire/ -- Poseida Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSTX#NASDAQ">PSTX</a>), a clinical-stage allogeneic cell therapy and genetic medicines company advancing differentiated non-viral treatments for patients with cancer, autoimmune, and rare diseases, today announced the upcoming presentation of new preclinical data supporting the potential of P-KLKB1-101, a liver-directed genetic medicine that uses the Company's Cas-CLOVER&#x2122;&nbsp;Site-Specific Gene Editing System, for the treatment of patients with hereditary angioedema (HAE). The data showed high-fidelity KLKB1 gene editing for the targeted correction of HAE, the ability for controlled dose response, favorable tolerability and liver editing within the predicted therapeutic range.

Poseida Therapeutics To Present New Preclinical Data Supporting Non-Viral Gene Editing With P-KLKB1-101 For The Treatment Of Hereditary Angioedema

Poseida Therapeutics Announces Nomination Of New CAR-T Development Candidate Under Collaboration with Roche, Triggering $15M Milestone Payment To Poseida

Poseida Therapeutics Reports Interim Phase 1 Results For Allogeneic CAR-T Therapy P-BCMA-ALLO1 Showing 91% ORR

Poseida Therapeutics shares are trading higher after the company received Regenerative Medicine Advanced Therapy designation from the FDA for P-BCMA-ALLO1 in relapsed/refractory multiple myeloma.

Poseida Therapeutics Receives Regenerative Medicine Advanced Therapy Designation From The FDA For P-BCMA-ALLO1 In Relapsed/Refractory Multiple Myeloma

Latest data from Poseida's lead investigational allogeneic CAR-T program, which is based on the Company's unique stem cell memory T cell (TSCM) platform
Company to host conference call on Saturday, September 28, 2024, at 1 PM ET / 10 AM PT to review the P-BCMA-ALLO1 Phase 1 IMS oral presentation data
Poseida initiates P-BCMA-ALLO1 Phase 1b clinical trial in patients with multiple myeloma, generating $20 million payment from Roche
SAN DIEGO, Sept. 5, 2024 /PRNewswire/ -- Poseida Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSTX#NASDAQ">PSTX</a>), a clinical-stage allogeneic cell therapy and genetic medicines company advancing differentiated non-viral treatments for patients with cancer and rare diseases, announced today that new clinical data from an ongoing Phase 1 study of P-BCMA-ALLO1 in patients with relapsed/refractory multiple myeloma will be presented in an oral session at the 21st International Myeloma Society (IMS) Annual Meeting, which is being held in Rio de Janeiro from September 25-28, 2024. The Company is developing P-BCMA-ALLO1, an investigational off-the-shelf allogeneic CAR-T cell therapy enriched for stem cell memory T cells (TSCM), in partnership with Roche for the treatment of relapsed/refractory multiple myeloma.

Contracts

Poseida Therapeutics To Present New Clinical Data From Phase 1 Study Of Allogeneic CAR-T P-BCMA-ALLO1 In Patients With Relapsed/Refractory Multiple Myeloma At 21st International Myeloma Society Annual Meeting; Initiation Of P-BCMA-ALLO1 Phase 1b Clinical Trial In Patients With Multiple Myeloma, Generated $20M Payment From Roche

William Blair analyst Sami Corwin has maintained their bullish stance on PSTX stock, giving a Buy rating on November 8. Sami Corwin has given his B...

Poseida Therapeutics: Promising Advancements and Strategic Collaborations Drive Buy Rating

H.C. Wainwright analyst Arthur He CFA has maintained their bullish stance on PSTX stock, giving a Buy rating today. Arthur He CFA has given his Buy...

Promising Advancements in Poseida Therapeutics' Cell Therapy Drive Buy Rating

In a report released today, Edward Tenthoff from Piper Sandler reiterated a Buy rating on Poseida Therapeutics (PSTX – Research Report), with a pri...

Poseida Therapeutics (PSTX) Receives a Buy from Piper Sandler

Poseida Therapeutics skyrockets 218% on $1.5B Roche acquisition offer

Biggest stock movers Tuesday: PSTX, SMTC, ALEC, LESL, WWD and more

Poseida Therapeutics (PSTX) announced that it has entered into a merger agreement to be acquired by Roche (RHHBY) at a price of $9.00 per share in ...

Poseida Therapeutics to be acquired by Roche for $9.00 per share plus CVR

Cantor Fitzgerald analyst Jennifer Kim downgraded Poseida Therapeutics (PSTX) to Neutral from Overweight without a price target after the company e...

Poseida Therapeutics downgraded to Neutral from Overweight at Cantor Fitzgerald

Poseida Therapeutics (PSTX – Research Report) received a Hold rating and price target from BTIG analyst Justin Zelin today. The company's shares cl...

Poseida Therapeutics (PSTX) was downgraded to a Hold Rating at BTIG

Poseida Therapeutics (PSTX – Research Report) received a Hold rating and price target from William Blair analyst Sami Corwin today. The company's s...

William Blair downgrades Poseida Therapeutics (PSTX) to a Hold

William Blair downgraded Poseida Therapeutics (PSTX) to Market Perform from Outperform after Roche (RHHBY) agreed to acquire Poseida for $13 per sh...

Comments

Poseida Therapeutics

Poseida Therapeutics (PSTX) 옵션

Poseida Therapeutics (NASDAQ:PSTX) 주식, 옵션 체인

뉴스

파트너 / 기고자

벤징가 글로벌